[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"drainage-procedure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:drainage-procedure":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100563841","a-national-study-examining-the-most-effective-drainage-method-after-burr-hole-evacuation-of-chronic-subdural-hematoma-100563841",false,"NCT06621407","A National Study Examining the Most Effective Drainage Method After Burr Hole Evacuation of Chronic Subdural Hematoma","Active 24 Hours Subperiostal vs. 24 Hours Passive Subdural Drainage Following Burr Hole Evacuation of Chronic Subdural Hematoma (the SUPERDURA Trial) - Protocol for a Nationwide Randomized Clinical Non-inferiority Trial","SUPERDURA","Inclusion Criteria:\n\n* Adult patients (≥ 18 years).\n* Patients with symptomatic CSDH confirmed on brain CT- or magnetic resonance imaging (MRI), admitted to a Danish neurosurgical department for surgical treatment.\n* Patients undergoing a single burr-hole evacuation.\n* Informed written and oral consent is taken prior to surgery.\n\nExclusion Criteria:\n\n* Patients who are mentally incapacitated\n* Patients with known abnormalities in their cerebrospinal fluid (protein and glucose levels, cell count, and type)\n* Patients with changes or abnormalities in their normal cerebrospinal fluid dynamics, e.g., obstructive hydrocephalus, normal pressure hydrocephalus, intracranial hypotension, and ventricular peritoneal shunt.\n* Patients with additional\u002Fpreviously intracranial pathology that requires\u002Fhas required neurosurgical treatment (e.g., brain tumor, vascular malformation, abscess).\n* Patients with recurrent CSDH or with previous craniotomy or other transcranial surgery (for any reason)\n* Patients unable to give consent prior to surgery","ALL","18 Years",{"count":20,"type":21},354,"ESTIMATED","INTERVENTIONAL",[24],"NA","Chronic subdural hematoma (CSDH) is a common disease. The main treatment is neurosurgical evacuation and subsequent hematoma drainage. However, consensus on the optimal drain placement site, and whether the drainage should be active or passive, is lacking.\n\nThe aim of the current study is to test the hypothesis that 24 hours active subperiosteal drainage is non-inferior to 24 hours passive subdural drainage after single burr hole evacuation of a unilateral CSDH.\n\nThe study is a multicenter randomized non-inferiority trial encompassing all neurosurgical units in Denmark.\n\nAdult patients with symptomatic CSDH admitted to a Danish neurosurgical unit for single burr hole evacuation will be screened for inclusion. Patients who are not able to give informed consent, and patients with recurrent CSDH, known cerebrospinal fluid abnormalities, and other known brain pathologies will be excluded. Patients with bilateral CSDH will be registered as one case and treated similarly on both sides.\n\nBefore surgical hematoma evacuation patients will be randomized to 24-hour passive subdural drainage or 24-hour active subperiosteal drainage.\n\nThe patients included and the two study statisticians will be blinded. The primary outcome is a composite outcome of 90-day mortality and symptomatic CSDH recurrence.\n\nSecondary outcomes are 90-day simplified modified Rankin score (smRSq), and complications related to surgery or occurring during admission, including intracerebral hemorrhage due to misplaced drains, acute subdural hematoma, tension pneumocephalus, wound infection, drain seepage, subperiosteal hematoma, thromboembolic events, infections and seizures.\n\nSample size simulations of non-inferiority with a threshold of 7% increased relative risk show that a total of 354 participants will be required to demonstrate a relative risk reduction of recurrent CSDH and mortality of 30% for the cohort receiving active subperiosteal drainage given a stable power above 80% with an alpha of 5%. The study inclusion period is estimated to last 2 years.\n\nEthics approval for inclusion of competent patients has been obtained (N-20240009).",[27,28,29,30,31,32,33],"Chronic Subdural Hematoma","Surgical Procedures, Operative","Recurrence","Mortality","Drainage","Drainage\u002FMethods","Drainage Procedure","RECRUITING","2025-11-20",{"date":37,"type":38},"2025-11-25","ACTUAL",{"date":40,"type":38},"2025-09-01",{"date":42,"type":21},"2027-11",{"name":44,"class":45},"Aalborg University Hospital","OTHER",4,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100377307","analysis-of-therapeutic-management-strategies-for-anal-suppurations-of-crohns-disease-100377307","NCT04192825","Analysis of Therapeutic Management Strategies for Anal Suppurations of Crohn's Disease","3T-LAP","Inclusion Criteria:\n\n* Persons over 18 years of age\n* People suffering from anal suppuration of Crohn's disease for whom a drainage procedure is planned.\n* Person who has received written and oral information about the protocol and has not expressed opposition to participate in the study.\n\nExclusion Criteria:\n\n* No one who is unable to have an anesthetic, structural or psychological examination by MRI and\u002For surgery.\n* Person planning a planned absence that could hinder participation in the research (travel abroad, relocation, impending transfer);\n* Person with an associated pathology that is a priority for care;\n* Vulnerable person (minors, persons under guardianship or curatorship, or deprived of their liberty by a judicial or administrative decision",{"count":55,"type":21},440,"OBSERVATIONAL","Determine the optimal therapeutic combination associated with complete clinical and anatomical remission of anal suppurations of Crohn's disease at 12 months.",[59,60,33],"Crohn Disease","Anal Suppurations","2023-04-11",{"date":63,"type":38},"2023-04-12",{"date":65,"type":38},"2020-02-03",{"date":67,"type":21},"2028-08-03",{"name":69,"class":45},"Rennes University Hospital",1]